Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02268175 · ClinicalTrials.gov registry record · Phase 2
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT02268175 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 75 participants.
The verdict
NCT02268175, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
This study is comparing the effectiveness of enzalutamide with or without abiraterone acetate for men with high-risk, localized prostate cancer.
Interventions
- DRUG Prednisone
- DRUG Enzalutamide
- DRUG Abiraterone Acetate
- DRUG Leuprolide Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2014-10 |
| Est. Completion | 2021-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02268175
The ClinicalTrials.gov registry entry for NCT02268175 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Prednisone is the first listed.
NCT02268175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02268175 about?
NCT02268175 is a clinical study titled "Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate". This study is comparing the effectiveness of enzalutamide with or without abiraterone acetate for men with high-risk, localized prostate cancer.
What is the current status of trial NCT02268175?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2014-10. Estimated completion is 2021-12.
What interventions are being tested in trial NCT02268175?
The interventions under investigation include: Prednisone (DRUG), Enzalutamide (DRUG), Abiraterone Acetate (DRUG), Leuprolide Acetate (DRUG).
Who is sponsoring clinical trial NCT02268175?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.